Zoetis Inc. (NYSE:ZTS) Receives $107.43 Consensus Target Price from Analysts

Shares of Zoetis Inc. (NYSE:ZTS) have received an average rating of “Hold” from the nineteen analysts that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and eight have issued a buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $101.0769.

Several brokerages recently weighed in on ZTS. Barclays cut their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. HSBC dropped their price objective on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, July 6th. Argus reissued a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Citigroup decreased their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Finally, William Blair reaffirmed a “market perform” rating on shares of Zoetis in a report on Thursday, August 6th.

Institutional Trading of Zoetis

A number of hedge funds have recently modified their holdings of the stock. NewEdge Advisors LLC grew its holdings in Zoetis by 43.0% during the second quarter. NewEdge Advisors LLC now owns 36,078 shares of the company’s stock worth $2,592,000 after acquiring an additional 10,855 shares during the period. Carmignac Gestion acquired a new position in Zoetis in the second quarter valued at approximately $113,230,000. Lipe & Dalton boosted its position in Zoetis by 26.5% in the 2nd quarter. Lipe & Dalton now owns 5,941 shares of the company’s stock worth $427,000 after purchasing an additional 1,243 shares in the last quarter. Empirical Finance LLC grew its stake in shares of Zoetis by 3.1% during the 2nd quarter. Empirical Finance LLC now owns 15,994 shares of the company’s stock worth $1,149,000 after purchasing an additional 481 shares during the period. Finally, Nykredit A S purchased a new position in shares of Zoetis during the 2nd quarter valued at approximately $10,042,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 3.0%

Shares of Zoetis stock opened at $73.56 on Friday. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. Zoetis has a 12-month low of $71.00 and a 12-month high of $152.12. The firm has a market capitalization of $30.40 billion, a price-to-earnings ratio of 12.12, a PEG ratio of 1.77 and a beta of 0.73. The firm’s 50 day simple moving average is $75.61 and its two-hundred day simple moving average is $92.87.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business’s quarterly revenue was down .2% on a year-over-year basis. During the same quarter last year, the company posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Analysts predict that Zoetis will post 6.2 EPS for the current year.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.